Wong Samford, Jamous Ali, O'Driscoll Jean, Sekhar Ravi, Saif Mofid, O'Driscoll Steve, Lewis Sarah, McKeown Eamonn, Hirani Shashi P
National Spinal Injuries Centre, Stoke Mandeville Hospital, Aylesbury, HP21 8AL, UK.
Centre for Health Services Research, City University, London, UK.
Syst Rev. 2015 Nov 24;4:170. doi: 10.1186/s13643-015-0159-3.
Probiotics may prevent antibiotic-associated and Clostridium difficile-associated diarrhoea (AAD/CDAD). Many spinal cord injury centre (SCIC) practitioners consider probiotics generically and may not realise that efficacy can be strain-, dose- and disease-specific. In order to confirm these effects and fully evaluate the extent of probiotic effectiveness in these patients, a systematic review and meta-analysis is indicated.
The following databases will be searched for relevant studies: Cochrane Library; Centre for Reviews and Dissemination (CRD) Database; CINAHL; PsycINFO; Embase; Medline; AMED; International Clinical Trials Registry Platform Search Portal and ISRCTN Registry and will hand search a list of conference proceedings. Any randomised controlled trials without restriction of publication status will be included with treatment of AAD/CDAD. Outcomes will include the effect of probiotic on the occurrence of AAD/CDAD and duration of diarrhoea, intensive care unit admission, hospital mortality and length of hospital stay. Two reviewers will independently screen the titles, abstracts or even full texts and extract data. Two other reviewers will assess study quality. Revman 5.1 software will be used to conduct meta-analysis and calculate the risk ratio for dichotomous data. Weighted mean difference or standard mean difference will be calculated for continuous data. The Cochrane Collaboration's tool will be used to assess the risk of bias.
This systematic review protocol will provide information on probiotic therapy for AAD and CDAD in spinal cord injury (SCI) population. The results will be disseminated through peer-reviewed publication or conference presentation.
PROSPERO CRD42015016976.
益生菌可能预防抗生素相关性腹泻及艰难梭菌相关性腹泻（AAD/CDAD）。许多脊髓损伤中心（SCIC）的从业者对益生菌的认识较为笼统，可能没有意识到其疗效具有菌株、剂量和疾病特异性。为了证实这些效果并全面评估益生菌对这些患者的有效性程度，有必要进行一项系统评价和荟萃分析。
将检索以下数据库以查找相关研究：Cochrane图书馆；综述与传播中心（CRD）数据库；护理学与健康领域数据库（CINAHL）；心理学文摘数据库（PsycINFO）；荷兰医学文摘数据库（Embase）；医学期刊数据库（Medline）；联合和补充医学数据库（AMED）；国际临床试验注册平台搜索入口及国际标准随机对照试验编号注册库，并将手工检索会议论文列表。纳入任何无发表状态限制的、治疗AAD/CDAD的随机对照试验。结局指标将包括益生菌对AAD/CDAD发生情况、腹泻持续时间、入住重症监护病房、医院死亡率及住院时间的影响。两名评价者将独立筛选标题、摘要甚至全文并提取数据。另外两名评价者将评估研究质量。将使用Revman 5.1软件进行荟萃分析并计算二分数据的风险比。对于连续数据，将计算加权均数差或标准化均数差。将使用Cochrane协作网的工具评估偏倚风险。
本系统评价方案将提供关于脊髓损伤（SCI）人群中益生菌治疗AAD和CDAD的信息。结果将通过同行评议发表或在会议上报告进行传播。
国际前瞻性系统评价注册库（PROSPERO）CRD42015016976
